scholarly article | Q13442814 |
P50 | author | Orit Itzhaki | Q92180479 |
Gal Markel | Q102132203 | ||
Liat Anafi | Q114337209 | ||
Eyal Greenberg | Q115760801 | ||
Yael Nemlich | Q115760802 | ||
Gilli Galore-Haskel | Q115760805 | ||
Jacob Schachter | Q55651283 | ||
P2093 | author name string | Michal J Besser | |
Motti Hakim | |||
Eytan Ben-Ami | |||
Efrat Ofek | |||
Shira Ashkenazi | |||
Noa Shoshani | |||
Ronnie Shapira-Fromer | |||
P2860 | cites work | ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing | Q24339141 |
ADAR1 interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of RNA editing | Q24529861 | ||
The role of microRNA genes in papillary thyroid carcinoma | Q24535848 | ||
RNA editing of a miRNA precursor | Q24540290 | ||
Modulation of microRNA processing and expression through RNA editing by ADAR deaminases | Q24594425 | ||
miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytes | Q24597200 | ||
Frequency and fate of microRNA editing in human brain | Q24653250 | ||
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
Widespread changes in protein synthesis induced by microRNAs | Q27860886 | ||
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma | Q28116578 | ||
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
Editing independent effects of ADARs on the miRNA/siRNA pathways | Q28256753 | ||
ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling | Q28591461 | ||
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
Redirection of silencing targets by adenosine-to-inosine editing of miRNAs | Q29619387 | ||
Systematic identification of abundant A-to-I editing sites in the human transcriptome | Q29619584 | ||
Systemic dysregulation of CEACAM1 in melanoma patients | Q84295467 | ||
Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
Widespread RNA editing of embedded alu elements in the human transcriptome | Q31108738 | ||
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. | Q31115813 | ||
Regulation of cancer aggressive features in melanoma cells by microRNAs | Q33889489 | ||
The synapse and cytolytic machinery of cytotoxic T cells | Q33913834 | ||
Expression profiling identifies microRNA signature in pancreatic cancer | Q34588109 | ||
Melanoma epidemiology and public health. | Q34605024 | ||
The structure, regulation, and function of ZAP-70. | Q34605479 | ||
Immune escape of tumors: apoptosis resistance and tumor counterattack. | Q34671704 | ||
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms | Q34770421 | ||
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. | Q34986356 | ||
A-to-I RNA editing: recent news and residual mysteries | Q35006724 | ||
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. | Q35617517 | ||
Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response | Q36192088 | ||
Adoptive cell therapy for the treatment of patients with metastatic melanoma | Q36283034 | ||
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth | Q36890980 | ||
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies | Q37000638 | ||
How tumours escape mass destruction | Q37287162 | ||
Adenosine-to-inosine RNA editing | Q37787949 | ||
Melanoma-associated antigen genes – An update | Q37811276 | ||
The mechanisms of cancer immunoescape and development of overcoming strategies | Q37849666 | ||
A-to-I RNA editing: the "ADAR" side of human cancer | Q37935255 | ||
Raising the bar: the curative potential of human cancer immunotherapy. | Q37998451 | ||
Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action | Q38012626 | ||
The influence of ADAR1's regulation on lymphocyte cell function during rejection | Q38350496 | ||
Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions | Q39371179 | ||
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway | Q39910342 | ||
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions | Q40216992 | ||
Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation | Q41412859 | ||
Roles for microRNAs in the regulation of cell adhesion molecules | Q41987634 | ||
RNA editing of human microRNAs | Q42113662 | ||
Spontaneous regression of melanoma | Q43944488 | ||
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies | Q45838316 | ||
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack | Q47632531 | ||
An immune-active tumor microenvironment favors clinical response to ipilimumab | Q56898024 | ||
Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation | Q73838333 | ||
P4510 | describes a project that uses | ImageQuant | Q112270642 |
P433 | issue | 30 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 28999-29015 | |
P577 | publication date | 2015-08-21 | |
P1433 | published in | Oncotarget | Q1573155 |
P1476 | title | A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme | |
P478 | volume | 6 |
Q26773402 | A-to-I editing of coding and non-coding RNAs by ADARs |
Q92593887 | ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications |
Q61813334 | ADAR1 Editing and its Role in Cancer |
Q91964806 | ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation |
Q99241375 | ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members |
Q55026245 | ADAR1-mediated regulation of melanoma invasion. |
Q37699205 | Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling |
Q42369277 | Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review |
Q28078188 | Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases |
Q47160476 | Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma. |
Q47225399 | Ipilimumab for the treatment of metastatic prostate cancer |
Q61417351 | MiRNAs in Malignant Melanoma |
Q90080352 | Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma |
Q95276547 | Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy |
Q60949658 | The Role of RNA Editing in Cancer Development and Metabolic Disorders |
Q46803210 | miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer |
Q47152593 | miRNAs, Melanoma and Microenvironment: An Intricate Network |
Q37197466 | microRNA editing in seed region aligns with cellular changes in hypoxic conditions |
Search more.